Aritzia Announces $200 Million Secondary Offering of Subordinate Voting Shares
ATRABrian Hill sells shares for estate planning, investment diversification and charitable giving purposes
January 13, 2026
Read more →Atara Biotherapeutics Announces Changes to Its Board of Directors
ATRA(NASDAQ:ATRA) THOUSAND OAKS, Calif--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Greg Ciongoli will assume the role of Chair of the Board of Directors. Greg Ciongoli is the founder and managing partner of Adiumentum Capital Management. He has served as a Director at Atara since 2024
September 3, 2025Board
Read more →Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
ATRATHOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2025 and business updates. Tabelecleucel (tab-cel® or Ebvallo™) for Post-Transplant Lymphoproliferative Disease (PTLD) The U.S. Food and Drug Administration (FDA) has
August 11, 2025Earnings
Read more →Atara Biotherapeutics Q1 EPS $3.50 Beats $(1.98) Estimate, Sales $98.15M Beat $5.67M Estimate
ATRAMay 15, 2025
Read more →Atara Biotherapeutics Prices Offering Of 834,237 Shares At $6.61/Shr And Pre-Funded Warrants At $6.6099 Per Pre-Funded Warrant Share In Underwritten Registered Direct Offering
ATRAMay 15, 2025
Read more →Atara Biotherapeutics Provides Regulatory Updates On EBVALLO; FDA Lifts Clinical Hold Enabling Resumption Of Clinical Trials; FDA Has Granted A Type A Meeting To Discuss Path Forward For BLA
ATRAMay 5, 2025
Read more →12 Health Care Stocks Moving In Thursday's Pre-Market Session
ATRAApril 24, 2025
Read more →Atara Biotherapeutics Transfers Full Manufacturing Responsibility For Tabelecleucel To Pierre Fabre; Now Entitled To Receive Up To $550M In Additional Potential Milestone Payments Upon Achieving Certain Regulatory And Commercial Milestones Relating To Tab
ATRAApril 4, 2025
Read more →Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Maintains $17 Price Target
ATRAMarch 11, 2025
Read more →Atara Biotherapeutics Q4 2024 GAAP EPS $(1.19) Beats $(3.58) Estimate, Sales $32.753 Miss $19.148M Estimate
ATRAMarch 7, 2025
Read more →Rodman & Renshaw Initiates Coverage On Atara Biotherapeutics with Buy Rating, Announces Price Target of $25
ATRADecember 20, 2024
Read more →HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeutics
ATRAMay 22, 2024
Read more →Atara Biotherapeutics Submits Tabelecleucel BLA For Treatment Of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease With U.S. FDA; Acceptance Of BLA Will Trigger $20M Milestone Payment From Pierre Fabre Laboratories, With Potential Fo
ATRAMay 20, 2024
Read more →Atara Biotherapeutics Earnings Preview
ATRAAtara Biotherapeutics (NASDAQ:ATRA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Atara Biotherapeutics will report an earnings per share (EPS) of $-0.98.
May 4, 2022
Read more →